Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
BX$119.20-6.38(-5.08%)MEDIA-Blackstone doubles lock-up periods for some Asian investors - FT7:06:27 PM ETSPG$226.72+0.17(+0.08%)Compared to Estimates, Simon Property (SPG) Q3 Earnings: A Look at Key Metrics7:01:18 PM ETEOG$144.890.00(0.00%)Compared to Estimates, EOG Resources (EOG) Q3 Earnings: A Look at Key Metrics7:01:12 PM ETMU$683.65-111.81(-14.06%)High Bandwidth Memory Market Outlook 2032: USD 15.99 Billion Valuation Driven by Advancements in Semiconductor Packaging | Mordor Intelligence7:00:00 PM ETJNJ$271.72-4.66(-1.69%)UPDATE 2-FDA grants J&J accelerated approval for head and neck cancer treatment6:53:59 PM ETNET$279.85+35.34(+14.45%)Cloudflare's stock mounts a big comeback after fastest sales surge in nearly 4 years6:50:00 PM ETPLTR$154.50-17.24(-10.04%)Palantir Is Down 16% From Its High. History Suggests This Is What Happens Next.6:45:00 PM ETNVDA$183.95+2.35(+1.29%)House G.O.P. Leaders Ask Nvidia's Huang to Speak in Closed-Door Briefing6:39:27 PM ETSNDK$839.76-197.42(-19.03%)Sandisk: This Is A Golden Opportunity6:18:30 PM ETPNC$226.750.00(0.00%)UPDATE 1-PNC names Alexander Overstrom as CFO, succeeding Robert Reilly6:11:49 PM ETAMD$414.71-73.98(-15.14%)Cathie Wood Just Sold AMD Stock and Bought This AI Chip Stock Instead6:00:00 PM ETBN$41.50-0.26(-0.62%)Brookfield Infrastructure Announces Update on Simplification5:50:00 PM ETVOYA-PB$23.360.00(0.00%)Corporate Insight Releases Research Series on AI Leaders in Financial Services5:48:25 PM ETJNJ$271.72-4.66(-1.69%)UPDATE 1-FDA grants J&J accelerated approval for head and neck cancer treatment5:47:37 PM ETCI$301.48-3.91(-1.28%)The Cigna Group (CI) Q3 2026 Earnings Call Transcript5:44:34 PM ETJNJ$271.72-4.66(-1.69%)FDA grants J&J accelerated approval for head and neck cancer treatment5:43:49 PM ETABNB$188.75+12.38(+7.02%)Airbnb says it's launching an AI travel agent in the first half of 20275:40:55 PM ETEOG$144.890.00(0.00%)UPDATE 3-US shale producer EOG Resources beats profit estimates on higher crude prices5:40:05 PM ETAMZN$257.01-9.18(-3.45%)Stock Market Today, Nov. 5: Amazon Shares Slide as Technology Selloff Erases Early Gains5:39:37 PM ETCNQ$49.12+0.20(+0.41%)Canadian Natural: Strong Results, 10%+ Yield5:39:28 PM ETSMCI$27.37-2.22(-7.50%)Super Micro: Major Plot Twist5:32:31 PM ETNVDA$183.95+2.35(+1.29%)Keep Calm, Stocks Are On Sale5:25:00 PM ETGS$869.08-59.20(-6.38%)UPDATE 1-Goldman Sachs lowers gold price forecasts on hawkish Fed outlook5:22:31 PM ETMRNA$234.25-24.09(-9.32%)Health Canada Authorizes Moderna's mRNA Influenza and Combination Influenza and COVID-19 Vaccines5:20:44 PM ET

ATYR · NASDAQ

aTyr Pharma, Inc.

$5.78 -0.40 (-6.47%)

Company overview

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease-related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis, and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has a collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$14.2M
Employees
56
Headquarters
San Diego, CA
Website
atyrpharma.com
CEO
Sanjay S. Shukla
Listed
May 7, 2015
P/E
-7.92
Dividend yield
0.00%

Company financials

Revenue
$190,000
Gross profit
-$22.3M
Operating income
-$73.3M
EBITDA
-$71M
Net income
-$70M
EPS
-$0.73
Total assets
$79.7M
Total debt
$11.7M
Gross margin
-11,754.74%
Net margin
-36,857.37%
Earnings yield
-12.63%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

-0.181.743.665.587.50
ATYR 1D NASDAQ O6.84H6.99L5.30C6.18-0.45 (-6.79%)Vol152.12K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
ATYRaTyr Pharma, Inc. Stock news ADVISORY-Alert on aTYR Pharma Q3 results wrongly sourced to Ethos Technology withdrawn Reuters
ATYRaTyr Pharma, Inc. Stock news CORRECTED-aTyr Pharma Q3 net loss narrows as expenses fall Reuters
ATYRaTyr Pharma, Inc. Press release aTyr Pharma Announces Third Quarter 2026 Results and Provides Corporate Update GlobeNewswire
ATYRaTyr Pharma, Inc. Press release aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine GlobeNewswire
ATYRaTyr Pharma, Inc. Press release aTyr Pharma Announces One-for-40 Reverse Stock Split GlobeNewswire
ATYRaTyr Pharma, Inc. Press release aTyr Pharma Announces Research Collaboration with Montefiore Einstein GlobeNewswire
ATYRaTyr Pharma, Inc. Press release aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry GlobeNewswire
ATYRaTyr Pharma, Inc. Stock news Financial Contrast: MeiraGTx (NASDAQ:MGTX) & aTyr Pharma (NASDAQ:ATYR) Defense World
ATYRaTyr Pharma, Inc. Stock news Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease Benzinga
ATYRaTyr Pharma, Inc. Press release aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis GlobeNewswire
ATYRaTyr Pharma, Inc. Press release aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis GlobeNewswire
ATYRaTyr Pharma, Inc. Press release aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD GlobeNewswire
ATYRaTyr Pharma, Inc. Press release aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026 GlobeNewswire
ATYRaTyr Pharma, Inc. Press release aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update GlobeNewswire
ATYRaTyr Pharma, Inc. Press release aTyr Pharma to Participate in Upcoming Investor Conferences GlobeNewswire
ATYRaTyr Pharma, Inc. Stock news aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoidosis After Phase III Results Transcript Seeking Alpha
ATYRaTyr Pharma, Inc. Stock news aTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trial MarketBeat
ATYRaTyr Pharma, Inc. Press release aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting GlobeNewswire
ATYRaTyr Pharma, Inc. Stock news aTyr Pharma Spotlights Efzofitimod Phase 3 Learnings, Eyes Mid-April FDA Type C Meeting Defense World
ATYRaTyr Pharma, Inc. Press release aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update GlobeNewswire
See more
FAQ

Questions about aTyr Pharma, Inc.

What does aTyr Pharma, Inc. do?
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease-related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis, and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has a collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan.
What is ATYR's market cap?
aTyr Pharma, Inc. (ATYR) is a listed stock with a live quote. The latest market cap on this page is $14.2M.
Where is aTyr Pharma, Inc. headquartered?
aTyr Pharma, Inc. is headquartered in San Diego, CA.
How do I get ATYR news from the API?
Call GET /v1/news?tickers=ATYR. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does ATYR news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for ATYR, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the ATYR price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs